Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2020-09, Vol.38 (27), p.3088-3094
Hauptverfasser:	Gul, Anita, Stewart, Tyler F, Mantia, Charlene M, Shah, Neil J, Gatof, Emily Stern, Long, Ying, Allman, Kimberly D, Ornstein, Moshe C, Hammers, Hans J, McDermott, David F, Atkins, Michael B, Hurwitz, Michael, Rini, Brian I
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - secondary Disease Progression Female Humans Immune Checkpoint Inhibitors - therapeutic use Ipilimumab - administration & dosage Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Middle Aged Nivolumab - administration & dosage Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival RAPID COMMUNICATIONS Retreatment Retrospective Studies Salvage Therapy Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!